Cerbios-Pharma has been acquired by HAS Healthcare
May 2025 — Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.
Cerbios is a Swiss company specializing in the development and manufacturing of both chemical and biological active pharmaceutical ingredients (APIs). In addition to advancing its own product pipeline, Cerbios offers third-party CDMO services for high potency active pharmaceutical ingredients (HPAPIs), recombinant proteins and antibody-drug conjugates (ADCs), supporting projects from preclinical development through to clinical and commercial supply.
HAS is a leading Swiss CDMO, specializing in high-potency substances. The company offers a full range of customized services, including laboratory development, manufacturing, regulatory support and approval. HAS develops and manufactures APIs, current good manufacturing practice (cGMP) advanced intermediates, HPAPIs and anticancer compounds exclusively for its clients, supporting projects from clinical development through to commercial supply.
Our role in the transaction
Oaklins’ team in Switzerland acted as the exclusive sell-side advisor to the shareholders and management of Cerbios, facilitating a successful transaction with the preferred partner.
Rudolf Dudler
Member of the board and co-owner, Cerbios-Pharma S.A.
Talk to the deal team
Daniel Eichenberger
Oaklins Switzerland
Related deals
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreAsana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.
Learn moreLaboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.
Learn more